Valeria Calabrese
YOU?
Author Swipe
View article: Ultrastructural Changes of Neuroendocrine Pheochromocytoma Cell Line PC-12 Exposed In Vitro to Rotenone
Ultrastructural Changes of Neuroendocrine Pheochromocytoma Cell Line PC-12 Exposed In Vitro to Rotenone Open
Rotenone is a pesticide used in research for its ability to induce changes similar, in vivo and in vitro, to those observed in Parkinson’s disease (PD). This includes a selective death of dopaminergic neurons in the substantia nigra. Nonet…
View article: The intricate debate on neurodegeneration and neuroinflammation in Parkinson’s disease: which came first?
The intricate debate on neurodegeneration and neuroinflammation in Parkinson’s disease: which came first? Open
Parkinson’s disease (PD) is a heterogeneous multifactorial disorder and, during the last years, new scientific evidence has supported this concept. The principal hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra …
View article: Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease
Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease Open
View article: Transcranial Magnetic Stimulation Exerts “Rejuvenation” Effects on Corticostriatal Synapses after Partial Dopamine Depletion
Transcranial Magnetic Stimulation Exerts “Rejuvenation” Effects on Corticostriatal Synapses after Partial Dopamine Depletion Open
Background In experimental models of Parkinson's disease (PD), different degrees of degeneration to the nigrostriatal pathway produce distinct profiles of synaptic alterations that depend on progressive changes in N‐methyl‐D‐aspartate rece…
View article: Serotonin drives striatal synaptic plasticity in a sex-related manner
Serotonin drives striatal synaptic plasticity in a sex-related manner Open
View article: Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease
Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson’s Disease Open
Parkinson’s disease (PD) is considered the most common disorder of synucleinopathy, which is characterised by intracellular inclusions of aggregated and misfolded α-synuclein (α-syn) protein in various brain regions, and the loss of dopami…
View article: Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting
Long-Term Shaping of Corticostriatal Synaptic Activity by Acute Fasting Open
Food restriction is a robust nongenic, nonsurgical and nonpharmacologic intervention known to improve health and extend lifespan in various species. Food is considered the most essential and frequently consumed natural reward, and current …
View article: Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia
Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia Open
Levodopa (L-DOPA) treatment is the main gold-standard therapy for Parkinson disease (PD). Besides good antiparkinsonian effects, prolonged use of this drug is associated to the development of involuntary movements known as L-DOPA-induced d…
View article: Author Correction: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease
Author Correction: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease Open
View article: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease
Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson's disease Open
Neuroinflammation is one of the hallmarks of Parkinson's disease (PD) and may contribute to midbrain dopamine (DA) neuron degeneration. Recent studies link chronic inflammation with failure to resolve early inflammation, a process operated…
View article: Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease
Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson’s disease Open
Neuroinflammation is one of the hallmarks of Parkinson’s disease (PD) and may contribute to midbrain dopamine (DA) neuron degeneration. Recent studies link chronic inflammation with failure to resolve early inflammation, a process operated…
View article: Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration Open
Parkinson's disease is a progressive neurodegenerative disorder characterized by altered striatal dopaminergic signalling that leads to motor and cognitive deficits. Parkinson's disease is also characterized by abnormal presence of soluble…
View article: Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration
Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration Open
Over the last two decades, many experimental and clinical studies have provided solid evidence that alpha-synuclein (α-syn), a small, natively unfolded protein, is closely related to Parkinson's disease (PD) pathology. To provide an overvi…